Page 35 - Aet News Today

Many hospitals remain underprepared to protect themselves against cybercriminals’ barrage of increasingly sophisticated attacks, but there are a couple concrete steps they can take to build a stronger defense structure — like virtual patching and thinking twice about moving to the cloud.

Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.

In looking ahead to 2024, the healthcare industry stands at the cusp of a transformative era of transparency. With impending regulatory changes and growing consumer empowerment, the landscape is poised for continued meaningful progress.

The contributors to food insecurity include age, having a disability, being on a fixed income and being a single parent, according to a recent report from FarmboxRx.

Hospitals and hospital systems need to make clearer and more consistent demands for climate accountability from their suppliers, and they need to follow through with preferred green vendor programs and the like.

Ambreen Molitor, Planned Parenthood’s national director of venture and innovation, discussed three partnerships her organization has launched this year to address barriers to abortion care. These partnerships tackle barriers such as cost, changing state laws and lack of emotional support.

AstraZeneca is paying $1 billion up front to acquire Gracell Biotechnologies, a clinical-stage cell therapy developer. The deal is the latest in a series of AstraZeneca moves intended to expand its presence in the burgeoning cell therapy field.

By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.

Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.

Current billing practices do not adequately meet the needs of consumers, providers or payers. While there is no magic wand, reinventing billing processes in the US will require measures that strengthen consumer protection, and continued policy change towards fairer drug pricing and increased price transparency of provider service costs.